GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Wiley  (5)
  • An, Jihyun  (5)
  • 1
    Online Resource
    Online Resource
    Comprehensive outcomes of on‐ and off‐antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis
    Wiley ; 2016
    In:  Journal of Medical Virology Vol. 88, No. 9 ( 2016-09), p. 1576-1586
    Details
    In: Journal of Medical Virology, Wiley, Vol. 88, No. 9 ( 2016-09), p. 1576-1586
    Abstract: Although antiviral prophylaxis is essential in hepatitis B patients in the context of cancer chemotherapy, there is little evidence‐based consensus regarding the appropriate prevention strategy depending on the underlying type of cancer and viral status. This retrospective study included a comprehensive cohort of 302 hepatitis B surface antigen‐positive patients with various cancers undergoing chemotherapy and antiviral prophylaxis. The rates of hepatitis B virus (HBV) reactivation during antiviral therapy ( 〉 1 log 10 IU/mL increase or positive conversion of serum HBV DNA) and relapse when off antivirals ([re]appearance of HBV DNA  〉 2,000 IU/ml with related alanine aminotransferase elevation) were evaluated, together with the associated risk factors, in a competing risks analysis where cancer death was considered as the competing event. During antiviral prophylaxis, HBV was reactivated in six patients (1.9%), who had leukemia (n = 4) or lymphoma (n = 2) and were treated with lamivudine (n = 4) or entecavir (n = 2). The incidence rate of HBV relapse in 127 off‐prophylaxis patients was 21.3% during a median post‐antiviral period of 11.7 months. Lymphoma, pre‐prophylactic HBV DNA ≥2,000 IU/ml, and age ≥50 years were independent predictors of off‐treatment HBV relapse (adjusted hazard ratios 5.25, 3.07, and 0.34, respectively; P s  〈  0.05). Antiviral and anticancer drugs, duration of consolidation on antiviral prophylaxis, and HBeAg positivity were not independent predictors. In conclusion, hepatitis B flare‐ups are not rare in patients receiving cancer chemotherapy during and after anti‐HBV prophylaxis, even when potent antivirals are used. Patients with hematopoietic or lymphoid neoplasms or high viral burdens should receive prolonged and powerful HBV prophylaxis. J. Med. Virol. 88:1576–1586, 2016 . © 2016 Wiley Periodicals, Inc.
    Type of Medium: Online Resource
    ISSN: 0146-6615 , 1096-9071
    URL: Issue
    URL: Article
    DOI: 10.1002/jmv.v88.9
    DOI: 10.1002/jmv.24512
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 752392-0
    detail.hit.zdb_id: 1475090-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Reappraisal of serum alpha‐foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment
    Wiley ; 2015
    In:  Liver International Vol. 35, No. 1 ( 2015-01), p. 232-239
    Details
    In: Liver International, Wiley, Vol. 35, No. 1 ( 2015-01), p. 232-239
    Abstract: The aim of this study was to re‐evaluate the diagnostic performance of alpha‐foetoprotein ( AFP ) as a surveillance test for hepatocellular carcinoma ( HCC ) in patients with hepatitis B virus‐related chronic liver disease who were treated with entecavir ( ETV ). Methods Between January 2007 and August 2012, we analysed 373 treatment‐naïve patients with HBV ‐related chronic hepatitis ( n  = 229) or cirrhosis ( n  = 144) who were candidates for surveillance test, and were treated with ETV (0.5 mg/day) for longer than 12 months. To minimize the effect of AFP elevation caused by hepatitis activity, serum AFP levels were measured 12 months after the initiation of ETV treatment. Results Hepatocellular carcinoma developed in 28 patients (7.5%) during a median follow‐up period of 48.0 months (IQR = 40.5–57.3 months). The area under the receiver operating characteristic curve for AFP was 0.71 (95% CI = 0.59–0.84). The optimal AFP cut‐off value was 13 ng/ml, leading to a sensitivity of 50.0%, specificity of 98.8%, positive predictive value of 77.8% and negative predictive value of 96.1%. In multivariate Cox analysis, an older age, the presence of cirrhosis and AFP levels of ≥20 ng/ml at 12 months after treatment were found to be significantly associated with an increased incidence of HCC. Conclusions The role of serum AFP as a surveillance test should be re‐evaluated in patients with HBV ‐related chronic liver diseases who were treated with antiviral therapy.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    URL: Article
    DOI: 10.1111/liv.2015.35.issue-1
    DOI: 10.1111/liv.12516
    Language: English
    Publisher: Wiley
    Publication Date: 2015
    detail.hit.zdb_id: 2102783-3
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Clinical characteristics and potential aetiologies of non‐B non‐C hepatocellular carcinoma in hepatitis B virus endemic area
    Wiley ; 2016
    In:  Liver International Vol. 36, No. 9 ( 2016-09), p. 1351-1361
    Details
    In: Liver International, Wiley, Vol. 36, No. 9 ( 2016-09), p. 1351-1361
    Abstract: We investigated potential aetiologies, clinical characteristics and prognosis of non‐B non‐C ( NBNC ) hepatocellular carcinoma ( HCC ) patients in hepatitis B virus ( HBV ) endemic area, according to potential causes such as previous HBV exposure, chronic alcohol intake and metabolic syndrome. Patients and Methods Among 4690 HCC patients treated at Asan Medical Center between 2007 and 2009, 523 were newly diagnosed with NBNC HCC , and their medical records and survival data were analyzed retrospectively. Results Among 321 NBNC HCC patients whose hepatitis B core antibody (anti‐ HB c) test results were available, 81.0%, 37.1% and 15.5% had anti‐ HB c positivity, chronic alcohol intake and metabolic syndrome respectively. One‐hundred and fifty‐two patients (47.4%) had previous exposure to HBV without chronic alcohol intake or metabolic syndrome. Hepatitis B surface antibody (anti‐ HB s) was positive in 48.0% of the 523 NBNC HCC patients, which was much lower than that in general Korean population, and 52.3% of anti‐ HB c‐positive NBNC HCC patients were negative for anti‐ HB s. Anti‐ HB c‐negative alcoholic patients presented with more advanced cirrhosis with Child‐Pugh class B/C liver function than anti‐ HB c‐positive patients ( P = 0.002). In multivariate analysis, baseline liver function, alpha‐foetoprotein levels and tumour stage were significant prognostic factors and aetiology did not affect patient survival. Conclusions Prior HBV infection could be a potential aetiology in over 40% of NBNC HCC patients in HBV endemic area. Positivity for anti‐ HB c and negativity for anti‐ HB s may be a serologic surrogate marker for occult HBV infection in these area. The prognosis of NBNC HCC was determined by tumour stage and underlying liver function.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    URL: Article
    DOI: 10.1111/liv.2016.36.issue-9
    DOI: 10.1111/liv.13099
    Language: English
    Publisher: Wiley
    Publication Date: 2016
    detail.hit.zdb_id: 2102783-3
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000‐Korean outcome study
    Wiley ; 2022
    In:  Journal of Viral Hepatitis Vol. 29, No. 9 ( 2022-09), p. 756-764
    Details
    In: Journal of Viral Hepatitis, Wiley, Vol. 29, No. 9 ( 2022-09), p. 756-764
    Abstract: Evidence on the carcinogenicity of oral nucleos(t)ide analogues (NAs) is inconclusive and lacks data on the effects by chemical structure of the NAs in patients with chronic hepatitis B (CHB). We aimed to provide definitive results on this issue using a large set of CHB patients and data on all major NA drugs. The study population consisted of 10,331 patients with CHB receiving primary NA treatment for more than 6 months, and 24,836 untreated controls followed for at least as long as the treated patients. Using the inverse‐probability‐of‐treatment‐weighted (IPTW) method, the cumulative incidence of extrahepatic cancers was compared in the treated and untreated patients and across the cyclopentane, L‐nucleoside and acyclic phosphonate categories of NAs. Analyses of individual cancers as sub‐endpoints were also performed. The cumulative incidence of overall extrahepatic malignancies did not differ between the two groups in the IPTW cohort (hazard ratio [HR] 1.002; 95% confidence interval [CI] [0.859–1.169] ). Similar statistical trends were observed in analyses across the three NA chemical subsets and controls. Per‐cancer analyses indicated that NA treatment was significantly associated with increased risks of colorectal/anal cancers (HRs [95% CI], 1.538 [1.175–2.013] ) and lymphoma (1.784 [1.196–2.662]). Conversely, breast cancer (HRs [95% CI] , 0.669 [0.462–0.967]) and prostate cancer (0.521 [0.329–0.825] ) were less prevalent in the NA‐treated group. In conclusion, prolonged NA treatment presents carcinogenic risks for colorectal/anal and lymphoid tissues in CHB patients, although it does not affect most extrahepatic organs. The protective effect of NAs on breast and prostate cancers should be confirmed.
    Type of Medium: Online Resource
    ISSN: 1352-0504 , 1365-2893
    URL: Issue
    URL: Article
    DOI: 10.1111/jvh.v29.9
    DOI: 10.1111/jvh.13721
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 1212497-7
    detail.hit.zdb_id: 2007924-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma
    Wiley ; 2021
    In:  Liver International Vol. 41, No. 10 ( 2021-10), p. 2499-2510
    Details
    In: Liver International, Wiley, Vol. 41, No. 10 ( 2021-10), p. 2499-2510
    Abstract: Chromophobe hepatocellular carcinoma (HCC) is a newly included subtype of HCC in the 5th edition of the WHO classification with distinctive histological features (chromophobic cytoplasm with anaplastic nuclei and pseudocyst formation) and is strongly associated with the alternative lengthening of telomeres (ALT) phenotype. However, the clinicopathologic characterization and molecular features of chromophobe HCC are unknown. Methods To comprehensively characterize chromophobe HCC, whole exome sequencing, copy number variation, and transcriptomic analyses were performed in 224 surgically resected HCC cases. Additionally, telomere‐specific fluorescence in situ hybridization was used to assess ALT. These genomic profiles and ALT status were compared with clinicopathological features among subtypes of HCC, particularly chromophobe HCC and conventional HCC. Results Chromophobe HCC was observed in 10.3% (23/224) cases and, compared to conventional HCC, was more frequent in females ( P  = .023). The overall and recurrence‐free survival outcomes were similar between patients with chromophobe HCC and conventional HCC. However, chromophobe HCC displayed significantly more upregulated genes involving cell cycle progression and DNA repair. Additionally, ALT was significantly enriched in chromophobe HCC (87%; 20/23) compared to conventional HCC (2.2%, 4/178; P   〈  .001). Somatic mutations in ALT‐associated genes, including ATRX , S MARCAL1 , FANCG , FANCM , SP100, TSPYL5 , and RAD52 were more frequent in chromophobe HCC (30.4%, 7/23 cases) compared to conventional HCC (11.8%, 21/178 cases; P  = .024). Conclusions Chromophobe HCC is a unique subtype of HCC with a prevalence of ~10%. Compared to conventional HCC, chromophobe HCC is associated with female predominance and ALT, although overall and recurrence‐free outcomes are similar to conventional HCC.
    Type of Medium: Online Resource
    ISSN: 1478-3223 , 1478-3231
    URL: Issue
    URL: Article
    DOI: 10.1111/liv.v41.10
    DOI: 10.1111/liv.14975
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2102783-3
    detail.hit.zdb_id: 2124684-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...